Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Price Target at $75.63

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus rating of “Hold” from the nineteen analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $75.63.

A number of brokerages have recently issued reports on CRSP. Needham & Company LLC dropped their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday, June 28th. Finally, Barclays lowered their target price on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently modified their holdings of CRSP. Global Trust Asset Management LLC raised its position in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Larson Financial Group LLC lifted its position in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its position in shares of CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after acquiring an additional 307 shares in the last quarter. Riggs Asset Managment Co. Inc. grew its position in shares of CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new stake in CRISPR Therapeutics during the 2nd quarter valued at approximately $35,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Trading Down 2.6 %

CRSP stock opened at $48.18 on Thursday. The stock has a market capitalization of $4.09 billion, a PE ratio of -17.71 and a beta of 1.68. The stock’s 50 day simple moving average is $50.45 and its 200 day simple moving average is $57.00. CRISPR Therapeutics has a 12-month low of $37.55 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter in the prior year, the firm posted ($0.98) earnings per share. CRISPR Therapeutics’s quarterly revenue was down 99.3% on a year-over-year basis. On average, research analysts predict that CRISPR Therapeutics will post -5.6 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.